| 1314024-48-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 1314024-48-0
• 化学式: C₃₃H₄₂N₄O₆S
• 分子量: 622.786
• InChiKey: OOZLHGAHQSDQTG-ZRRKCSAHSA-N

物化性质

• 密度：
  1.277±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.72
• 重原子数：
  44.0
• 可旋转键数：
  8.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  130.09
• 氢给体数：
  3.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以94%的产率得到2-(2-amino-1,3-thiazol-4-yl)-N-[4-({(2S,5R)-[(R)-hydroxy(phenyl)methyl]pyrrolidinyl}methyl)phenyl]acetamide
  参考文献：
  名称：

  Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists

  摘要：

  A novel class of human beta(3)-adrenergic receptor agonists was designed in effort to improve selectivity and metabolic stability versus previous disclosed beta(3)-AR agonists. As observed, many of the beta(3)-AR agonists seem to need the acyclic ethanolamine core for agonist activity. We have synthesized derivatives that constrained this moiety by introduction of a pyrrolidine. This unique modification maintains human beta(3) functional potency with improved selectivity versus ancillary targets and also eliminates the possibility of the same oxidative metabolites formed from cleavage of the N-C bond of the ethanolamine. Compound 39 exhibited excellent functional beta(3) agonist potency across species with good pharmacokinetic properties in rat, dog, and rhesus monkeys. Early de-risking of this novel pyrrolidine core (44) via full AMES study supports further research into various new beta(3)-AR agonists containing the pyrrolidine moiety. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.087
• 作为产物：
  描述：

  4-({(5R)-5-[(R)-([tert-butyl(dimethyl)silyl]oxy)(phenyl)methyl]pyrrolidin-2-yl}methyl)aniline 在 N-羟基-7-氮杂苯并三氮唑 、 四丁基氟化铵 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists

  摘要：

  A novel class of human beta(3)-adrenergic receptor agonists was designed in effort to improve selectivity and metabolic stability versus previous disclosed beta(3)-AR agonists. As observed, many of the beta(3)-AR agonists seem to need the acyclic ethanolamine core for agonist activity. We have synthesized derivatives that constrained this moiety by introduction of a pyrrolidine. This unique modification maintains human beta(3) functional potency with improved selectivity versus ancillary targets and also eliminates the possibility of the same oxidative metabolites formed from cleavage of the N-C bond of the ethanolamine. Compound 39 exhibited excellent functional beta(3) agonist potency across species with good pharmacokinetic properties in rat, dog, and rhesus monkeys. Early de-risking of this novel pyrrolidine core (44) via full AMES study supports further research into various new beta(3)-AR agonists containing the pyrrolidine moiety. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.087